45,109 Shares in Enliven Therapeutics, Inc. $ELVN Bought by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 45,109 shares of the company’s stock, valued at approximately $2,289,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. TimesSquare Capital Management LLC acquired a new position in Enliven Therapeutics in the 2nd quarter worth $13,263,000. Persistent Asset Partners Ltd acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at about $479,000. Bank of New York Mellon Corp bought a new stake in shares of Enliven Therapeutics in the second quarter valued at about $6,032,000. State of Wyoming bought a new stake in shares of Enliven Therapeutics in the second quarter valued at about $96,000. Finally, Tema ETFs LLC boosted its position in shares of Enliven Therapeutics by 41.0% during the second quarter. Tema ETFs LLC now owns 60,694 shares of the company’s stock worth $3,080,000 after buying an additional 17,638 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Enliven Therapeutics

In related news, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the sale, the director directly owned 41,884 shares in the company, valued at $2,114,723.16. The trade was a 19.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $58.58, for a total value of $352,534.44. Following the transaction, the chief financial officer owned 40,036 shares in the company, valued at $2,345,308.88. The trade was a 13.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 196,849 shares of company stock worth $11,344,257 over the last quarter. Company insiders own 3.00% of the company’s stock.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $60.50 on Friday. The company has a market cap of $4.43 billion, a P/E ratio of -36.23 and a beta of 0.27. The firm’s fifty day moving average price is $54.36 and its two-hundred day moving average price is $42.99. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ELVN. Stifel Nicolaus increased their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. HC Wainwright boosted their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. The Goldman Sachs Group upped their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. William Blair began coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating for the company. Finally, JonesTrading lifted their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics has an average rating of “Moderate Buy” and an average price target of $75.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.